Navigation Links
Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
Date:10/28/2008

ates. Due to the asymptomatic nature of HCV infection, it often goes undetected for up to 20 years following initial infection. Each year, 8,000 to 10,000 people in the United States die from complications of HCV.

The current standard of care is a combination of pegylated interferon and ribavirin. Inadequate response rates, in particular for patients infected with genotype 1 HCV, along with significant side effects of approved therapy support the medical need for improved treatment options. It is estimated that fewer than 5% of people with chronic HCV infection living in the United States are under treatment today. Most infected individuals are unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents: ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statemen
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Anadys Pharmaceuticals to Present at Bio Investor Forum
2. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
5. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
6. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
7. Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908
8. Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008
9. Avidas Pharmaceuticals Signs Agreement to Acquire North American Rights to Products That Address Chronic Dermatologic Conditions
10. Genesis Pharmaceuticals Received New Purchase Orders Worth $12 Million
11. ISTA Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)Wind Turbines are popping up in the most unusual places, and to do everything from growing mushrooms, making wine to keeping prisoners in jail! , (PRWEB) December 5, 2009 -- W
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)KANSAS CITY, Mo., Dec. 4 The large, two-day free health clinic sponsored by the National Association of Free Clinics (NAFC) in Kansas City on Wednesday and Thursday is not just for the sick but also
(Date:12/4/2009)WASHINGTON, Dec. 4 In response to the U.S. Justice Department Drug Enforcement Agency,s (DEA) classification of boldione, desoxymethyltestosterone, and 19-nor-4,9(10)-androstadienedione as "anabolic
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
Breaking Medicine News(10 mins):Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Natural Products Association Issues Statement on DEA's Steroid Classification Action 2Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2
...icials across UK are participating in a dummy exer...y bird flu pandemic. The preparation may be s...n Britain are wary of a bird flu epidemic hitting ... chiefly in birds, but infections with these virus...
...s have developed an experimental vaccine that redu...d with cytomegalovirus// (CMV). This virus also ca...n children infected in early fetal life. The Natio... no vaccine or treatment for pregnant women who ha...
...er Anoushka Shankar has become the first Indian ce...o fight against hunger in India//. She joins...ollywood star Drew Barrymore and footballer Ronald...ause. I will personally do whatever I can to raise...
... a haven for migratory birds, is gearing up to tac...ases// of the deadly virus. "We are watching...industry to take certain protective measures," sai...lu had been reported yet from any part of the stat...
...ounterfeit drugs are being circulated in South Asi...ingitis, typhoid//, pneumonia and avian flu. Accor...iane, the drugs have been well disguised making it... treated with the original drug. They also add tha...
...to a report released by International Federation o...a has been hit by measles//. This disease has so f...people are said to be affected by this illness. ... cases pointing to the spread of the disease. The ...
Other Medicine News:Health News:Dummy Emergency Operation Launched 2Health News:CMV Vaccine Prototype Successfully Tested in Guinea Pigs 2Health News:CMV Vaccine Prototype Successfully Tested in Guinea Pigs 3
(Date:12/3/2009)SUNNYVALE, Calif., Dec. 3 Pharmacyclics, Inc. (Nasdaq: PCYC ), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune media
(Date:12/3/2009)WARRENDALE, Pa., Dec. 3 Radiology imaging leader MEDRAD, Inc. demonstrated PACS* injection-record integration capabilities at the November 2009 Radiology Society of North America in Chicago. The Co
(Date:12/3/2009)FORT WORTH, Texas, Dec. 3 Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), a rapidly growing provider of specialty medical products, announced today an agreement with the Health In
Breaking Medicine Technology:Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 2Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up 3West Announces Third Quarter 2009 Results 5943 1West Announces Third Quarter 2009 Results 5943 2West Announces Third Quarter 2009 Results 5943 3West Announces Third Quarter 2009 Results 5943 4West Announces Third Quarter 2009 Results 5943 5West Announces Third Quarter 2009 Results 5943 6West Announces Third Quarter 2009 Results 5943 7West Announces Third Quarter 2009 Results 5943 8West Announces Third Quarter 2009 Results 5943 9West Announces Third Quarter 2009 Results 5943 10West Announces Third Quarter 2009 Results 5943 11West Announces Third Quarter 2009 Results 5943 12West Announces Third Quarter 2009 Results 5943 13West Announces Third Quarter 2009 Results 5943 14West Announces Third Quarter 2009 Results 5943 15West Announces Third Quarter 2009 Results 5943 16West Announces Third Quarter 2009 Results 5943 17West Announces Third Quarter 2009 Results 5943 18West Announces Third Quarter 2009 Results 5943 19West Announces Third Quarter 2009 Results 5943 20West Announces Third Quarter 2009 Results 5943 21West Announces Third Quarter 2009 Results 5943 22Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 1Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 2Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 3Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 4Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 5Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 6Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 7Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 8Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 9Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 10Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 11Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 12Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 13Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 14Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 15Regeneron Reports Third Quarter 2009 Financial and Operating Results 5939 16Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients 14698 1Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients 14698 2Experimental Stem Cell Therapy Raises Hope for Pulmonary Fibrosis Patients 14698 3
...48-week investigational regimen yielded nearly dou...ate on next-generation HCV protease inhibitor SCH ...HAGEN, Denmark, April 23 Schering-Plough Corporat...ts of the HCV SPRINT-1 study showed boceprevir, it...tor, in combination with peginterferon alfa-2b and...
... , , , FDA approval for testing in humans water..., , ROCKVILLE, Md., April 23 In a move that high...n in tackling international health challenges, the... from the PATH Malaria Vaccine Initiative (MVI), h... tests in adult volunteers -- of its unique malari...
Other Medicine Technology:Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 2Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 3Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin 4
...G-9200 is a Windows 2000 PC based EEG with high pe... and software. EEG-9200 provides high quality perf...in the sleep lab or EEG lab. Quality EEG recording...CU. Neurofax has high performance, high sensitivit...
...act is the first magnetic stimulator to offer the ... stimulation. It is designed to provide the simple...tic routine (at the same time, it may also help re...ons without moving away from your patient). , ,...
Fidelity IAB Intra-Aortic Balloon Catheter
...series is a new top-line range of digital pacemake...rillation (AF). Because the T-series combines digi...reatment of AF is taken one step further. Thanks t...ored continuously and extensively. This gives phys...
Medicine Products: